Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):862–864. doi: 10.1038/bjc.1990.395

Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine.

N M Barnes 1, J Ge 1, W G Jones 1, R J Naylor 1, J A Rudd 1
PMCID: PMC1971539  PMID: 2173945

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. L., Rapeport W. G., Sanger G. J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci. 1988 Sep;9(9):334–341. doi: 10.1016/0165-6147(88)90106-x. [DOI] [PubMed] [Google Scholar]
  2. Costall B., Domeney A. M., Naylor R. J., Tattersall F. D. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology. 1986 Aug;25(8):959–961. doi: 10.1016/0028-3908(86)90030-4. [DOI] [PubMed] [Google Scholar]
  3. Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Finn A. L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990 Mar 22;322(12):810–816. doi: 10.1056/NEJM199003223221204. [DOI] [PubMed] [Google Scholar]
  4. Cunningham D., Hawthorn J., Pople A., Gazet J. C., Ford H. T., Challoner T., Coombes R. C. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1987 Jun 27;1(8548):1461–1463. doi: 10.1016/s0140-6736(87)92208-2. [DOI] [PubMed] [Google Scholar]
  5. Feldman J. M., Plonk J. W., Cornette J. C. Serum prostaglandin F-2 alpha concentration in the carcinoid syndrome. Prostaglandins. 1974 Sep 25;7(6):501–506. doi: 10.1016/0090-6980(74)90094-x. [DOI] [PubMed] [Google Scholar]
  6. Hawthorn J., Ostler K. J., Andrews P. L. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol. 1988 Jan;73(1):7–21. doi: 10.1113/expphysiol.1988.sp003124. [DOI] [PubMed] [Google Scholar]
  7. Higgins G. A., Kilpatrick G. J., Bunce K. T., Jones B. J., Tyers M. B. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989 May;97(1):247–255. doi: 10.1111/j.1476-5381.1989.tb11948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kris M. G., Gralla R. J., Clark R. A., Tyson L. B. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst. 1989 Jan 4;81(1):42–46. doi: 10.1093/jnci/81.1.42. [DOI] [PubMed] [Google Scholar]
  9. Leibundgut U., Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet. 1987 May 23;1(8543):1198–1198. doi: 10.1016/s0140-6736(87)92159-3. [DOI] [PubMed] [Google Scholar]
  10. Marty M., Pouillart P., Scholl S., Droz J. P., Azab M., Brion N., Pujade-Lauraine E., Paule B., Paes D., Bons J. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990 Mar 22;322(12):816–821. doi: 10.1056/NEJM199003223221205. [DOI] [PubMed] [Google Scholar]
  11. Miner W. D., Sanger G. J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986 Jul;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ortiz J., Artigas F., Gelpí E. Serotonergic status in human blood. Life Sci. 1988;43(12):983–990. doi: 10.1016/0024-3205(88)90543-7. [DOI] [PubMed] [Google Scholar]
  13. Tyce G. M., Creagan E. T. Measurement of free and bound 5-hydroxytryptophan in plasma by liquid chromatography with electrochemical detection. Anal Biochem. 1981 Mar 15;112(1):143–150. doi: 10.1016/0003-2697(81)90271-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES